Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 2/20 | 0.40 |
| ▸ | METTL3 | Q86U44 | 4/20 | 0.32 |
| ▸ | KDR | P35968 | 1/20 | 0.31 |
| ▸ | TEK | Q02763 | 1/20 | 0.31 |
| ▸ | ALOX5 | P09917 | 4/20 | 0.31 |
| ▸ | ABL1 | P00519 | 1/20 | 0.31 |
| ▸ | SRC | P12931 | 1/20 | 0.31 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16749746 | 0.92 | BTK (0.48) | BTKMETTL3KDRTEKALOX5 | |
| SCHEMBL16749773 | 0.85 | BTK (0.35) | BTKMETTL3 | |
| SCHEMBL15614923 | 0.84 | BTK (0.42) | BTKABL1SRCMAP4K4 | |
| SCHEMBL16749600 | 0.84 | BTK (0.43) | BTKMETTL3 | |
| SCHEMBL16749601 | 0.82 | BTK (0.41) | BTKMETTL3ALOX5 | |
| SCHEMBL16749767 | 0.81 | BTK (0.35) | BTKALOX5 | |
| SCHEMBL15615083 | 0.77 | EGFR (0.45) | BTK | |
| SCHEMBL15615076 | 0.76 | BTK (0.49) | BTKMETTL3ABL1SRC | |
| SCHEMBL16749747 | 0.76 | BTK (0.51) | BTKMETTL3 | |
| SCHEMBL15615065 | 0.75 | BTK (0.42) | BTKMETTL3ALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160289236-A1 | Protein Kinase Inhibitors | PHARMASCIENCE INC. (CA) | 2016-10-06 | — | — | US | disclosed |
| US-20160289236-A1 | Protein Kinase Inhibitors | PHARMASCIENCE INC. (CA) | 2016-10-06 | — | — | US | disclosed |
| WO-2015074135-A1 | PROTEIN KINASE INHIBITORS | PHARMASCIENCE INC. (CA) | 2015-05-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160289236-A1 | Protein Kinase Inhibitors | TEC, LCK, SRC | BTK 6/4885METTL3 4103/4885KDR 2191/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.